Castle Biosciences Net Worth
Castle Biosciences Net Worth Breakdown | CSTL |
Castle Biosciences Net Worth Analysis
Castle Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Castle Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Castle Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Castle Biosciences' net worth analysis. One common approach is to calculate Castle Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Castle Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Castle Biosciences' net worth. This approach calculates the present value of Castle Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Castle Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Castle Biosciences' net worth. This involves comparing Castle Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Castle Biosciences' net worth relative to its peers.
To determine if Castle Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Castle Biosciences' net worth research are outlined below:
| Castle Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 219.79 M. Net Loss for the year was (57.47 M) with profit before overhead, payroll, taxes, and interest of 105.03 M. | |
| Castle Biosciences currently holds about 273.17 M in cash with (5.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.39. | |
| Castle Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Castle Biosciences Inc Shares Up 3.52 percent on Nov 26 |
Castle Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Castle Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Castle Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Castle Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Castle Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Castle Biosciences backward and forwards among themselves. Castle Biosciences' institutional investor refers to the entity that pools money to purchase Castle Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Palisade Capital Management Llc | 2024-09-30 | 502.3 K | Point72 Asset Management, L.p. | 2024-09-30 | 499.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 498.8 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 496.5 K | Renaissance Technologies Corp | 2024-09-30 | 489.6 K | Granahan Investment Management Inc.. | 2024-09-30 | 425.2 K | Kornitzer Capital Management Inc | 2024-09-30 | 407.2 K | Braidwell Lp | 2024-09-30 | 332 K | Deutsche Bank Ag | 2024-06-30 | 309.5 K | Blackrock Inc | 2024-06-30 | 3 M | Wasatch Advisors Lp | 2024-09-30 | 1.8 M |
Follow Castle Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 852.54 M.Market Cap |
|
Project Castle Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.15) | (0.14) |
When accessing Castle Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Castle Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Castle Biosciences' profitability and make more informed investment decisions.
Evaluate Castle Biosciences' management efficiency
The value of Return On Tangible Assets is estimated to slide to -0.18. The value of Return On Capital Employed is expected to slide to -0.18. At this time, Castle Biosciences' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 2.8 M this year, although the value of Net Tangible Assets will most likely fall to about 181.4 M. Castle Biosciences' management efficiency ratios could be used to measure how well Castle Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.60 | 8.66 | |
| Tangible Book Value Per Share | 10.22 | 7.20 | |
| Enterprise Value Over EBITDA | (10.99) | (11.54) | |
| Price Book Value Ratio | 1.48 | 1.55 | |
| Enterprise Value Multiple | (10.99) | (11.54) | |
| Price Fair Value | 1.48 | 1.55 | |
| Enterprise Value | 223.1 M | 198.4 M |
Understanding the operational decisions made by Castle Biosciences management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 1.9222 | Revenue 311.9 M | Quarterly Revenue Growth 0.395 | Revenue Per Share 11.34 | Return On Equity 0.0147 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Castle Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Castle Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Castle Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Castle Biosciences Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Castle Biosciences Earnings per Share Projection vs Actual
Castle Biosciences Corporate Management
| Camilla Zuckero | Exec Communications | Profile | |
| John Abbott | VP Controller | Profile | |
| RN RN | Chief Officer | Profile | |
| Kristen RN | Chief Officer | Profile | |
| Tobin Juvenal | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.21 | Revenue Per Share 11.34 | Quarterly Revenue Growth 0.395 | Return On Assets (0) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.